If this is the case, and if there is no causality between the use of prolactin-increasing antipsychotics and breast cancer, then there is an urgent need for better screening of risk factors, both those that are modifiable (eg, physical inactivity, obesity, excessive alcohol consumption, smoking, use of hormone replacement therapy) and nonmodifiable risk factors (eg, positive family history, low parity, early menarche, late menopause, genes such as BRCA1/2), with appropriate interventions to mitigate some of the associated risks and routine breast cancer screening during treatment. The gene discussed is PRL; the disease is breast carcinoma.